Table of Content

Introduction
Executive Summary
Respiratory syncytial virus infections: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Respiratory syncytial virus infections – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Respiratory syncytial virus infections companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Respiratory syncytial virus infections Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
GSK3844766A: GlaxoSmithKline
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report?..
Mid Stage Products (Phase II)
• Comparative Analysis
EDP 938: Enanta Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report?..
Early Stage Products (Phase I)
• Comparative Analysis
mRNA-1345: Moderna Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report?..
Preclinical and Discovery Stage Products
• Comparative Analysis
AR-201: Aridis Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report?..

Inactive Products
• Comparative Analysis
Respiratory syncytial virus infections Key Companies
Respiratory syncytial virus infections Key Products
Respiratory syncytial virus infections- Unmet Needs
Respiratory syncytial virus infections- Market Drivers and Barriers
Respiratory syncytial virus infections- Future Perspectives and Conclusion
Respiratory syncytial virus infections Analyst Views
Respiratory syncytial virus infections Key Companies
Appendix



List of Figures

Figure 1 Total Products for Respiratory syncytial virus infections
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

List of Tables

Table 1 Total Products for Respiratory syncytial virus infections
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products